On Apr. 27, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events. AIM also reported no SAEs in Cohort 1. The study was proceeding with enrollment into Cohort 3.